Current methods of anti-angiogenic influence on newly formed corneal vessels

Voevodina T.M.; Fedorov A.A.; Budzinskaia M.V.

doi:https://doi.org/

Close metadata

Recommended articles:

Biomechanical control of myopia: potential of bidirectional corneal applanation with high-speed video recording. Russian Annals of Ophthalmology. 2024;(5):25-32

Efficacy of brolucizumab in the treatment of retinal pathologies: a review of post-marketing studies. Russian Annals of Ophthalmology. 2024;(5):154-161

Management of patients with treatment-resistant neovascular age-related macular degeneration. Russian Annals of Ophthalmology. 2024;(6):63-68

Choroidal neovascularization associated with choroidal nevi. Russian Annals of Ophthalmology. 2025;(1):104-112

Modern possibilities of using photodynamic therapy with an intravenous sensitizer as an alternative to surgical treatment: a clinical case of successful. Russian Journal of Human Reproduction. 2024;(6):149-155

Photodynamic inactivation of antibiotic-resistant microflora of gunshot wounds under fluorescence control. Pirogov Russian Journal of Surgery. 2025;(2):50-59

Substantiation of the anti-inflammatory effect of photodynamic therapy in periodontal diseases. Russian Journal of Stomatology. 2025;(1):40-45

Comparative assessment of the onychomycosis phototherapy methods efficacy. Russian Journal of Clinical Dermatology and Venereology. 2025;(3):313-318

Photodynamic and microcurrent therapy in rehabilitation after facial plastic surgery. Plastic Surgery and Aesthetic Medicine. 2025;(2-2):65-68

Method of photodynamic action in surgical treatment of local limited peritonitis in the experiment. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2-2):77-86

Abstract:

Russian and foreign literature data on current methods of anti-angiogenic influence on newly formed corneal vessels in experiment and clinic was analyzed. Their advantages and negative effects are highlighted and the information about their combined use is provided. The conclusion about the need of further studies is made.

Keywords:

cornea

neovascularization

photodynamic therapy

antiangiogenic therapy

Authors:

Voevodina T.M.

FGBU "NII glaznykh bolezneĭ" RAMN

Fedorov A.A.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Budzinskaia M.V.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

SPIN RSCI: 3552-7061
Scopus AuthorID: 6508005851
ResearcherID: C-3026-2014
ORCID: 0000-0002-5507-8775

Close metadata

References:

Agaeva T.S. Neovaskulyarizatsiya prozrachnoi rogovitsy pri sakharnom diabete. (Klinicheskie primery pri razlichnykh stadiyakh razvitiya sakharnogo diabeta). Novoe v diagnostike i lechenii glaznykh zabolevanii. 1991; 43-52.
Budzinskaya M.V. Vozmozhnost' primeneniya otechestvennogo preparata "Fotosens" pri fluorestsentnoi diagnostike i fotodinamicheskoi terapii opukholevykh i psevdoopukholevykh zabolevanii glaz (eksperimental'noe issledovanie): Dis. .. kand. med. nauk. M 2004; 174.
Kiselev G.L., Loshchenov V.B. Raspredelenie lazernogo izlucheniya v biologicheskoi tkani pri fotodinamicheskoi terapii i diagnostike. Ros khim zhurn 1998; XLII: 53-64.
Kopaeva V.G., Andreev Yu.V., Ponomarev G.V. i dr. Pervyi opyt lecheniya neovaskulyarizatsii rogovichnogo transplantata metodom fotokhimicheskoi destruktsii sosudov. Aktual'nye problemy oftal'mologii. Sbornik nauchnykh trudov. Ufa 1996; 40-42.
Libman E.S. S''ezd oftal'mologov Rossii, 8-i: Materialy. 2005; 3-5.
Luk'yanets E.A. Novye sensibilizatory dlya fotodinamicheskoi terapii. Fotodinamicheskaya terapiya: Materialy III vserossiiskogo simpoziuma. 1999; 117-128.
Maichuk Yu.F. Novoe v epidemiologii i farmakoterapii glaznykh infektsii. Klin oftal'mol 2000; 1: 2: 48-51.
Maklakova I.A. Neovaskulyarizatsiya rogovitsy. Sovremennye aspekty patogeneza i lecheniya. Vestn. Oftal'mologii 1993; 109: 5: 35-38.
Mertvetsov N.P., Stefanovich L.E. Angiogenin i mekhanizm angiogeneza. Novosibirsk: Nauka. Sib. predpriyatie RAN 1997; 78.
Mironov A.F. Fotosensibilizatory na osnove porfirinov i rodstvennykh soedinenii. Itogi nauki i tekhniki. Sovremennye problemy lazernoi fiziki. M: VINITI 1990; 3: 224.
Parfenova E.V., Tkachuk V.A. Terapevticheskii angiogenez: dostizheniya, problemy, perspektivy. Kardiol vestn 2007; 2.
Sobolev A.S., Rozenkrats A.A., Akhlynina T.V. Napravlennyi vnutrikletochnyi transport fotosensibilizatorov. Ros khim zhurn 1998; XLII: 5: 84-88.
Stranadko E.F. Mekhanizmy deistviya fotodinamicheskoi terapii. Fotodinamicheskaya terapiya: Materialy III vserossiiskogo simpoziuma. 1999; 3-15.
Yuzhakov A.M., Bykov V.P., Zyurnyaeva I.D., Gogadze M.G. Novye perspektivy v lechenii vnutriglaznoi infektsii. Vest oftal'mol 2000; 2: 20-22.
Azar D.T. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing. Trans Am Ophthalmol Soc 2006; 104: 264-302.
Bahar I., Kaiserman I., McAllum P., Rootman D., Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008; 27: 2: 142-147.
Barr H., Kendall C., Reyes-Goddard J., Stone N. Clinical aspects of photodynamic therapy. Sci Prog 2002; 85: 131-150.
Barros L.F.M., Belfort R. Jr. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. Anais da Academia Brasileira de Ciê
Bock F., Onderka J., Dietrich T., Bachmann B., Kruse F.E., Paschke M. et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48: 2545-2552.
Bock F., König Y., Kruse F., Baier M., Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008; 246: 2: 281-284.
Cherry P.M.H., Garner A. Corneal neovascularization treated with argon laser. Brit J Ophthalmol 1976; 60: 464-472.
Coman L., Coman O.A., Păunescu H., Drăghia F., Fulga I. VEGF-induced corneal neovascularisation in a rabbit experimental model. Rom J Morphol Embryol 2010; 51: 2: 327-336.
D'Amore P.A., Smith S.R. Growth factor effects on cells of the vascular wall: survey. Growht Factors 1993: 8: 61-75.
DeRosa M.C., Crutchley R.J. Photosensitized singlet oxygen and its applications. Coord Chem Rev 2002; 233-234: 351-371.
Doctor P.P., Bhat P.V., Foster C.S. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008; 27: 9: 992-995.
Ecoiffier T., Yuen D., Chen L. Differential distribution of blood and lymphatic vessels in the murine cornea. Invest Ophthalmol Vis Sci 2010: 51: 5: 2436-2440.
Edelman J.L., Castro M.R., Wen Y. Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest Ophthalmol Vis Sci 1999; 40: 6: 1112-1123.
Fossarello M., Peiretti E., Zucca I., Serra A. Photodynamic therapy of corneal neovascularization with verteporfirin. Cornea 2003; 22: 5: 485-488.
Fromer C.H., Klintworth G.K. An evaluation of the role of leukocytes in the pathogenesis of experimentally induced corneal. Am J Pathol 1976; 82: 1: 157-170.
Gerten G. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 2008; 27: 10: 1195-1199.
Gohto Y., Obana A., Kaneda K., Miki T. Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization. Exp Eye Res 1998; 67: 3: 313-322.
Han Y.S., Lee J.E., Jung J.W., Lee J.S. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247: 4: 541-548. Epub. 2008. Oct 25.
Henderson B.W., Donovan J.M. Release of proslaglandin E2 from cells by photodynamic treatment. Cancer Res 1989; 49: 6896-6790.
Holzer M.P., Solomon K.D., Vroman D.T. Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 2954-2958.
Horowitz A., Simons M. Celastrol nanoparticles inhibit corneal neovascularization induced by suturing in rats. Int J Nanomed 2012; 7: 1163-1173.
Hosseini H., Nejabat M., Mehryar M., Yazdchi T., Dedaghat A., Noon F. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 2007; 35: 8: 745-748.
Hough R.B., Piatigorsky J. Preferential transcription of rabbit aldh1a1 in the cornea: implication of hypoxia-related pathways. Mol Cell Biol 2004; 24: 3: 1324-1340.
Kernt M., Welge-Lüssen U., Yu A., Neubauer A.S., Kampik A. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe 2007: 104: 11: 965-971.
Kim I., Ryan A.M., Rohan R., Amano S., Agular S., Miller J.W., Adamis A.P. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 1999; 40: 2115-2121.
Kim J.H., Kim J.C., Shin S.H., Chang S.I., Lee H.S., Chung S.I. The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF. Exp Mol Med 1999; 31: 4: 203-209.
Liu G.Q., Lu P.R., Li L.B., Zhang X.G. Inhibited experimental corneal neovascularization by neutralizing anti-SDF-1α antibody. Int J Ophthalmol 2012; 5: 1: 7-12.
Loschenov V.B., Konov V.I., Prokhorov A.M. Photodynamic therapy and fluorescence diagnostics. Laser Physics 2000; 10: 1188-1207.
Ma X., Ottino P., Bazan H.E., Bazan N.G. Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells. Invest Ophthalmol Vis Sci 2004; 45: 2915-2921.
Mazhdrakova I., Demerdjieva Z. Neovascularisation of the cornea. Klin Monatsbl Augenheilkd 2005; 222: 8: 623-629.
Nakamura M., Nishida T. Differential effects of epidermal growth factor and interleukin 6 on corneal epithelial cells and vascular endothelial cells. Cornea 1999; 18: 4: 452-458.
Neels H.M., Vanden Berghe D.A., Neetens A.J., Delgadillo R.A., Scharpe S.L. Angiotensin I converting enzyme activity in rabbit corneal endothelial cells. Ophthalmologica 1983; 187: 2: 129-132.
Nirankari V.S. Laser photocoagulation for corneal stromal vascularization. Trans Am Ophthalmol Soc 1992; 90: 595-669.
Nezu E., Ohashi Y., Kinoshita S., Manabe R. Recombinant human epidermal growth factor and corneal neovascularization. Jpn J Ophthalmol 1992; 36: 4: 401-406.
O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 2: 315-328.
Prokofyeva E., Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: A literature review. Ophthalmic Res 2012; 47: 171-188.
Qazi Y., Maddula S., Ambati B.K. Mediators of ocular angiogenesis. J Genet 2009; 88: 4: 495-515.
Shiota N., Saegusa Y., Nishimura K., Miyaraki M. Angiotensin II-generating system in dog and monkey ocular tissues. Clin Exp Pharmacol Physiol 1997; 24: 3-4: 243-248.
Spitzer M.S., Wallenfels-Thilo B., Sierra A., Yoeruek E., Peters S., Henke-Fahle S. et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006; 90: 10: 1316-1321.
Tombren-Tink J., Barnstable C.J. Ocular Angiogenesis: Diseases, mechanisms, and therapeutics. Humana press 2006; 412.
Usui T., Sugisaki K., Iriyama A., Yakoo S., Yamagami S., Nagai N. et al. Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2008; 49: 10: 4370-4376.
Yoeruek E., Ziemssen F., Henke-Fahle S., Tatar O., Tura A., Grisanti S. et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol 2008; 86: 3: 322-328.
Zhang H., Hu X., Tse J., Tilahun F., Qiu M., Chen L. Spontaneous lymphatic vessel formation and regression in the murine cornea. Invest Ophthalmol Vis Sc 2011; 52: 1: 334-338.